News und Analysen
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Aug. 5, 2021, following the release of its second
Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection.
“This acquisition is procompetitive, and we have
Agilent Technologies Celebrates More than 20 Years of Sustainable Progress
Agilent Technologies, Inc. (NYSE: A) today issued its 21st annual Corporate Social Responsibility (CSR) report. The report highlights the company’s progress in critical environmental, social and
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the
STAAR Surgical to Report Second Quarter Results on August 4, 2021
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
2021 HALF-YEAR BOIRON ACTIVITY
Cumulative Activity as of the end of june 2021
In thousands of euros 2020 2021 Variation at current exchange rates Variation at constant exchange rates France 104,930 126,32
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis’ senior management
Agilent to Webcast Third-Quarter Fiscal Year 2021 Financial Results Presentation
Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, August 17. The company will host a live webcast of its
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African
Nanobiotix Provides Second Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to
Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)
Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the
IMV Inc. Closes Previously Announced Public Offering
IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the closing of its previously-announced underwritten public offering
Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds
Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS)
Sensorion Appoints Ex-Novartis Cell Therapy & Viral Vectors Head Otmane Boussif as Chief Technical Officer
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Eyenovia will be
Pfizer Announces New Investor Relations Leader
Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo has joined the company as Senior Vice President and Chief Investor Relations Officer, reporting to Chief Corporate Affairs Officer
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it
FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today